The prime time for management of hepatocellular carcinoma in Hong Kong

Clin Mol Hepatol. 2023 Apr;29(2):345-348. doi: 10.3350/cmh.2023.0094. Epub 2023 Mar 9.

Authors

Landon L Chan¹, Stephen L Chan^{1

2}

Affiliations

¹ Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.
² State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong, China.

No abstract available

Keywords: Chemoembolization; Hepatocellular carcinoma; Immune checkpoint inhibitors; Lenvatinib.

Publication types

Editorial
Comment

MeSH terms

Carcinoma, Hepatocellular* / pathology
Carcinoma, Hepatocellular* / therapy
Chemoembolization, Therapeutic*
Hong Kong
Humans
Liver Neoplasms* / pathology
Liver Neoplasms* / therapy
Phenylurea Compounds

Substances

Phenylurea Compounds

Grants and funding